Rani Therapeutics Holdings, Inc. (RANI) financial statements (2022 and earlier)

Company profile

Business Address 2051 RINGWOOD AVENUE
SAN JOSE, CA 95131
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

Current Assets
Cash, cash equivalents, and short-term investments117,453
Cash and cash equivalents117,453
Prepaid expense2,142
Total current assets:119,595
Noncurrent Assets
Property, plant and equipment4,612
Total noncurrent assets:4,612
Current Liabilities
Accounts payable and accrued liabilities2,514
Accounts payable1,080
Accrued liabilities1,434
Due to related parties126
Total current liabilities:2,640
Noncurrent Liabilities
Total liabilities:2,640
Stockholders' equity
Stockholders' equity attributable to parent, including:47,411
Additional paid in capital55,737
Accumulated deficit(8,331)
Other undisclosed stockholders' equity attributable to parent5
Stockholders' equity attributable to noncontrolling interest74,156
Total stockholders' equity:121,567

Income statement (P&L) ($ in thousands)

Gross profit:2,717
Operating expenses54,316
Other undisclosed operating loss(108,632)
Operating loss:(51,599)
Nonoperating income
(Investment Income, Nonoperating)
Interest and debt expense(1,166)
Loss from continuing operations before equity method investments, income taxes:(52,676)
Other undisclosed loss from continuing operations before income taxes(371)
Loss from continuing operations before income taxes:(53,047)
Income tax expense(41)
Net loss:(53,088)
Net income attributable to noncontrolling interest44,757
Net loss available to common stockholders, diluted:(8,331)

Comprehensive Income ($ in thousands)

Net loss:(53,088)
Comprehensive loss:(53,088)
Comprehensive income, net of tax, attributable to noncontrolling interest44,757
Comprehensive loss, net of tax, attributable to parent:(8,331)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: